Prime Medicine (PRME) EBIT (2021 - 2026)
Prime Medicine's (PRME) quarterly EBIT came in at -$50.7 million in Q1 2026, up 3.32% YoY from -$49.0 million in Q1 2025, and down 4.21% on a QoQ basis from -$48.6 million in Q4 2025.
Prime Medicine (PRME) EBIT (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of EBIT data on file, last reported at -$50.7 million in Q1 2026.
- Quarterly EBIT rose 3.32% year-over-year to -$50.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$206.6 million (changed 0.05% YoY) and the FY2025 annual result came in at -$208.4 million, down 2.91% from the prior year.
- EBIT declined to -$50.7 million in Q1 2026, from -$48.6 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$19.9 million in Q1 2022 to a low of -$68.0 million in Q4 2023.
- A 5-year average of -$46.0 million and a median of -$48.6 million in 2025 frame the typical range for EBIT.
- The widest YoY moves for EBIT: up 35.6% in 2022, down 203.59% in 2022.
- Tracing PRME's EBIT over 5 years: stood at -$38.7 million in 2022, then plunged by 75.89% to -$68.0 million in 2023, then soared by 35.01% to -$44.2 million in 2024, then decreased by 9.92% to -$48.6 million in 2025, then dropped by 4.21% to -$50.7 million in 2026.
- The last three EBIT figures came in at -$50.7 million (Q1 2026), -$48.6 million (Q4 2025), and -$54.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | -43.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.29 Mn |
| Mar 31, 2026 | -50.65 Mn |
| Dec 31, 2025 | -48.61 Mn |
| Sep 30, 2025 | -53.97 Mn |
| Jun 30, 2025 | -53.38 Mn |
| Mar 31, 2025 | -52.39 Mn |
| Dec 31, 2024 | -44.22 Mn |
| Sep 30, 2024 | -54.23 Mn |
| Jun 30, 2024 | -55.67 Mn |
| Mar 31, 2024 | -48.34 Mn |
| Dec 31, 2023 | -68.04 Mn |
| Sep 30, 2023 | -51.46 Mn |
| Jun 30, 2023 | -45.26 Mn |
| Mar 31, 2023 | -40.03 Mn |
| Dec 31, 2022 | -38.69 Mn |
| Sep 30, 2022 | -31.66 Mn |
| Jun 30, 2022 | -26.31 Mn |
| Mar 31, 2022 | -19.90 Mn |
| Dec 31, 2021 | -60.08 Mn |
| Sep 30, 2021 | -10.43 Mn |